ALK mutations confer differential oncogenic activation and sensitivity to ALK inhibition therapy in neuroblastoma.

Genetic studies have established anaplastic lymphoma kinase (ALK), a cell surface receptor tyrosine kinase, as a tractable molecular target in neuroblastoma. We describe comprehensive genomic, biochemical, and computational analyses of ALK mutations across 1,596 diagnostic neuroblastoma samples. ALK tyrosine kinase domain mutations occurred in 8% of samples--at three hot spots and 13 minor sites--and correlated significantly with poorer survival in high- and intermediate-risk neuroblastoma. Biochemical and computational studies distinguished oncogenic (constitutively activating) from nononcogenic mutations and allowed robust computational prediction of their effects. The mutated variants also showed differential in vitro crizotinib sensitivities. Our studies identify ALK genomic status as a clinically important therapeutic stratification tool in neuroblastoma and will allow tailoring of ALK-targeted therapy to specific mutations.

[1]  S. Grupp,et al.  Late effects in survivors of tandem peripheral blood stem cell transplant for high‐risk neuroblastoma , 2008, Pediatric blood & cancer.

[2]  Jon C. Aster,et al.  Efficient and Rapid Induction of a Chronic Myelogenous Leukemia-Like Myeloproliferative Disease in Mice Receiving P210 bcr/abl-Transduced Bone Marrow , 1998 .

[3]  Glen Spraggon,et al.  Crystal structure of the ALK (anaplastic lymphoma kinase) catalytic domain. , 2010, The Biochemical journal.

[4]  C. Ottmann,et al.  The neuroblastoma ALK(I1250T) mutation is a kinase- dead RTK in vitro and in vivo , 2011 .

[5]  J. Christensen,et al.  Activating ALK mutations found in neuroblastoma are inhibited by Crizotinib and NVP-TAE684. , 2011, The Biochemical journal.

[6]  M. Karplus,et al.  Hidden thermodynamics of mutant proteins: a molecular dynamics analysis. , 1989, Science.

[7]  C. Naeve,et al.  ALK, the chromosome 2 gene locus altered by the t(2;5) in non-Hodgkin's lymphoma, encodes a novel neural receptor tyrosine kinase that is highly related to leukocyte tyrosine kinase (LTK) , 1997, Oncogene.

[8]  Nicholas M. Glykos,et al.  Software news and updates carma: A molecular dynamics analysis program , 2006, J. Comput. Chem..

[9]  J. C. Clemens,et al.  Expression, purification, and physicochemical characterization of a recombinant Yersinia protein tyrosine phosphatase. , 1992, The Journal of biological chemistry.

[10]  D N Shapiro,et al.  Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. , 1994, Science.

[11]  J. Maris,et al.  Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study. , 2013, The Lancet. Oncology.

[12]  D. Engelman,et al.  Dimerization of the p185neu transmembrane domain is necessary but not sufficient for transformation , 1997, Oncogene.

[13]  A. Knudson,et al.  Mutation and cancer: neuroblastoma and pheochromocytoma. , 1972, American journal of human genetics.

[14]  Helen X. Chen,et al.  Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. , 2010, The New England journal of medicine.

[15]  Michael A. Dyer,et al.  Neuroblastoma: developmental biology, cancer genomics and immunotherapy , 2013, Nature Reviews Cancer.

[16]  Wei Zheng,et al.  The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers. , 2010, Cancer research.

[17]  S. Henikoff,et al.  Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm , 2009, Nature Protocols.

[18]  John M. Maris,et al.  Identification of ALK as a major familial neuroblastoma predisposition gene , 2008, Nature.

[19]  M. Marra,et al.  Cell culture and Drosophila model systems define three classes of anaplastic lymphoma kinase mutations in neuroblastoma , 2012, Disease Models & Mechanisms.

[20]  L. Tanoue,et al.  Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer , 2012 .

[21]  Jaroslav Bendl,et al.  PredictSNP: Robust and Accurate Consensus Classifier for Prediction of Disease-Related Mutations , 2014, PLoS Comput. Biol..

[22]  Hiroshi Sakamoto,et al.  CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant. , 2011, Cancer cell.

[23]  O. Delattre,et al.  ALK germline mutations in patients with neuroblastoma: a rare and weakly penetrant syndrome , 2011, European Journal of Human Genetics.

[24]  Alexander D. MacKerell,et al.  All-atom empirical potential for molecular modeling and dynamics studies of proteins. , 1998, The journal of physical chemistry. B.

[25]  Mingming Jia,et al.  COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer , 2010, Nucleic Acids Res..

[26]  N. Olgun,et al.  Copy number status and mutation analyses of anaplastic lymphoma kinase (ALK) gene in 90 sporadic neuroblastoma tumors. , 2012, Cancer letters.

[27]  Wei Liu,et al.  Discovery of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) with preclinical brain expos , 2014, Journal of medicinal chemistry.

[28]  M. Klein,et al.  Constant pressure molecular dynamics algorithms , 1994 .

[29]  Huichun Zhu,et al.  Discovery of (10R)-7-Amino-12-Fluoro-2,10,16-Trimethyl-15-Oxo-10,15,16,17-Tetrahydro-2H-8,4-(Metheno)Pyrazolo[4,3-H][2,5,11]Benzoxadiazacyclotetradecine-3-Carbonitrile (Pf-06463922), a Macrocyclic Inhibitor of Alk/Ros1 with Pre-Clinical Brain Exposure and Broad Spectrum Potency Against Alk-Resistant , 2014 .

[30]  S. Altekruse,et al.  Outcomes for children and adolescents with cancer: challenges for the twenty-first century. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  X. Estivill,et al.  Activating Mutations Cluster in the “Molecular Brake” Regions of Protein Kinases and Do Not Associate with Conserved or Catalytic Residues , 2014, Human mutation.

[32]  R. Palmer,et al.  Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology , 2013, Nature Reviews Cancer.

[33]  E. Connolly,et al.  Chromosome 1p and 11q Deletions and Outcome in Neuroblastoma. , 2006, Neurosurgery.

[34]  D. Gary Gilliland,et al.  Activating mutations in ALK provide a therapeutic target in neuroblastoma , 2008, Nature.

[35]  P. Kollman,et al.  Settle: An analytical version of the SHAKE and RATTLE algorithm for rigid water models , 1992 .

[36]  J. Engelman,et al.  ALK in lung cancer: past, present, and future. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  M. L. Connolly.  Solvent-accessible surfaces of proteins and nucleic acids. , 1983, Science.

[38]  Ryohei Katayama,et al.  Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK , 2011, Proceedings of the National Academy of Sciences.

[39]  Andrea Lombardi Borgia,et al.  Crystal structures of anaplastic lymphoma kinase in complex with ATP competitive inhibitors. , 2010, Biochemistry.

[40]  Ravi Radhakrishnan,et al.  Erlotinib binds both inactive and active conformations of the EGFR tyrosine kinase domain , 2012, The Biochemical journal.

[41]  L. Scapozza,et al.  Unique substrate specificity of anaplastic lymphoma kinase (ALK): development of phosphoacceptor peptides for the assay of ALK activity. , 2005, Biochemistry.

[42]  F. Gnad,et al.  Assessment of computational methods for predicting the effects of missense mutations in human cancers , 2013, BMC Genomics.

[43]  D. Machin,et al.  High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial. , 2008, The Lancet. Oncology.

[44]  Makoto Nishio,et al.  The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. , 2014, Cancer discovery.

[45]  Huaqing Zhao,et al.  Differential Inhibitor Sensitivity of Anaplastic Lymphoma Kinase Variants Found in Neuroblastoma , 2011, Science Translational Medicine.

[46]  Yael Mosse,et al.  Detection of Single-Copy Chromosome 17q Gain in Human Neuroblastomas Using Real-Time Quantitative Polymerase Chain Reaction , 2003, Modern Pathology.

[47]  T. Clackson,et al.  Crizotinib-Resistant Mutants of EML4-ALK Identified Through an Accelerated Mutagenesis Screen , 2011, Chemical biology & drug design.

[48]  P. Axelsen,et al.  Improved convergence in dual‐topology free energy calculations through use of harmonic restraints , 1998 .

[49]  Jan Hellemans,et al.  Accurate and objective copy number profiling using real-time quantitative PCR. , 2010, Methods.

[50]  Kiran C. Bobba,et al.  Discovery of Novel Recurrent Mutations in Childhood Early T-Cell Precursor Acute Lymphoblastic Leukemia by Whole Genome Sequencing - a Report From the St Jude Children's Research Hospital - Washington University Pediatric Cancer Genome Project , 2011 .

[51]  B. Brooks,et al.  Constant pressure molecular dynamics simulation: The Langevin piston method , 1995 .

[52]  R. Radhakrishnan,et al.  Molecular dynamics analysis of conserved hydrophobic and hydrophilic bond-interaction networks in ErbB family kinases. , 2011, The Biochemical journal.

[53]  M. Cole,et al.  High Frequency of p53/MDM2/p14ARF Pathway Abnormalities in Relapsed Neuroblastoma , 2010, Clinical Cancer Research.

[54]  Young Lim Choi,et al.  EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. , 2010, The New England journal of medicine.

[55]  Jinghui Zhang,et al.  Association of age at diagnosis and genetic mutations in patients with neuroblastoma. , 2012, JAMA.

[56]  Hiroyuki Shimada,et al.  Chromosome 1p and 11q deletions and outcome in neuroblastoma. , 2005, The New England journal of medicine.

[57]  Renee Emkey,et al.  The R1275Q Neuroblastoma Mutant and Certain ATP-competitive Inhibitors Stabilize Alternative Activation Loop Conformations of Anaplastic Lymphoma Kinase* , 2012, The Journal of Biological Chemistry.

[58]  T. Arakawa,et al.  Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system , 1997, Oncogene.

[59]  J. Maris.  Recent advances in neuroblastoma. , 2010, The New England journal of medicine.

[60]  A. Mark,et al.  Avoiding singularities and numerical instabilities in free energy calculations based on molecular simulations , 1994 .

[61]  K Schulten,et al.  VMD: visual molecular dynamics. , 1996, Journal of molecular graphics.

[62]  Laxmikant V. Kalé,et al.  Scalable molecular dynamics with NAMD , 2005, J. Comput. Chem..

[63]  Gudrun Schleiermacher,et al.  Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma , 2008, Nature.

[64]  H. Aburatani,et al.  Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer , 2007, Nature.

[65]  Frank Speleman,et al.  Meta-analysis of Neuroblastomas Reveals a Skewed ALK Mutation Spectrum in Tumors with MYCN Amplification , 2010, Clinical Cancer Research.

[66]  H. C. Andersen.  Rattle: A “velocity” version of the shake algorithm for molecular dynamics calculations , 1983 .

[67]  P. Bork,et al.  A method and server for predicting damaging missense mutations , 2010, Nature Methods.

[68]  Ben M. Webb,et al.  Comparative Protein Structure Modeling Using Modeller , 2006, Current protocols in bioinformatics.

[69]  S. Ogawa,et al.  Oncogenic mutations of ALK kinase in neuroblastoma , 2008, Nature.

[70]  S. Hubbard.  Crystal structure of the activated insulin receptor tyrosine kinase in complex with peptide substrate and ATP analog , 1997, The EMBO journal.

[71]  D. Beveridge,et al.  Free energy via molecular simulation: applications to chemical and biomolecular systems. , 1989, Annual review of biophysics and biophysical chemistry.